Trials / Completed
CompletedNCT02856451
Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab
Case Series Analyses of the Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 486 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A case series analysis of encephalitis events reported to the Sponsor for patients treated with nivolumab to assess the risk factors and outcomes of immune-mediated encephalitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
Timeline
- Start date
- 2015-12-09
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
- First posted
- 2016-08-04
- Last updated
- 2022-06-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02856451. Inclusion in this directory is not an endorsement.